Work

Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.2588

Authors: Heloisa Veasey Rodrigues, JoAnn Lim, Bettzy Stephen, Filip Janku, Apostolia Maria Tsimberidou, Sarina Anne Piha-Paul, Siqing Fu, Aung Naing, Vivek Subbiah, Gerald Steven Falchook, Razelle Kurzrock, Jennifer J. Wheler

Institutions: Hospital Israelita Albert Einstein, The University of Texas MD Anderson Cancer Center, HealthONE, Moores Cancer Center

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597504118

Cites:

Cited by: 2

Related to: 10